GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Buyback Yield %

Chimeric Therapeutics (ASX:CHM) Buyback Yield % : -49.12 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Chimeric Therapeutics's current buyback yield was -49.12%.


Chimeric Therapeutics Buyback Yield % Historical Data

The historical data trend for Chimeric Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Buyback Yield % Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Buyback Yield %
-38.13 -34.73 -12.92

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial - - - - -53.38

Competitive Comparison of Chimeric Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Chimeric Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimeric Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Buyback Yield % falls into.



Chimeric Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Chimeric Therapeutics's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.089 + 2.577) / 19.254068
=-12.92%

Chimeric Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.788 + 7.568) * 2 / 25.404435
=-53.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Chimeric Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines